Institute of Medicinal Biotechnology, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China.
Key Laboratory of the Ministry of Education for Advanced Catalysis Materials, Department of Chemistry, Zhejiang Normal University, Jinhua 321004, China.
Int J Mol Sci. 2022 Nov 16;23(22):14178. doi: 10.3390/ijms232214178.
With the increasing prevalence of drug-resistant variants, novel potent HIV-1 protease inhibitors with broad-spectrum antiviral activity against multidrug-resistant causative viruses are urgently needed. Herein, we designed and synthesized a new series of HIV-1 protease inhibitors with phenols or polyphenols as the P2 ligands and a variety of sulfonamide analogs as the P2' ligands. A number of these new inhibitors showed superb enzymatic inhibitory activity and antiviral activity. In particular, inhibitors and exhibited potent enzymatic inhibitory activity in the low picomolar range, and the latter showed excellent activity against the Darunavir-resistant HIV-1 variant. Furthermore, the molecular modeling studies provided insight into the ligand-binding site interactions between inhibitors and the enzyme cavity, and they sparked inspiration for the further optimization of potent inhibitors.
随着耐药变异体的日益流行,急需具有广谱抗多种耐药致病病毒活性的新型强效 HIV-1 蛋白酶抑制剂。在此,我们设计并合成了一系列以酚类或多酚类为 P2 配体、各种磺酰胺类似物为 P2' 配体的新型 HIV-1 蛋白酶抑制剂。这些新抑制剂中的许多都表现出极好的酶抑制活性和抗病毒活性。特别是抑制剂 和 表现出低皮摩尔级别的强效酶抑制活性,而后者对达芦那韦耐药的 HIV-1 变异体表现出极好的活性。此外,分子建模研究深入了解了抑制剂与酶腔之间的配体结合位点相互作用,为进一步优化强效抑制剂提供了启示。